TargetMol

Bendamustine hydrochloride

Product Code:
 
TAR-T0095
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0095-25mg25mg£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0095-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0095-50mg50mg£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0095-100mg100mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0095-200mg200mg£244.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0095-500mg500mg£361.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Bendamustine hydrochloride (IC50 of 50 μM) is an alkylating agent associated with DNA damage.
CAS:
3543-75-7
Formula:
C16H22Cl3N3O2
Molecular Weight:
394.72
Pathway:
Apoptosis; Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.9803
SMILES:
Cl.Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl
Target:
Apoptosis; DNA Alkylator/Crosslinker; DNA/RNA Synthesis

References

1. Leoni LM, et al. Clin Cancer Res. 2008, 14(1), 309-317. 2. Schw?nen C, et al. Leukemia. 2002, 16(10), 2096-2105. 3. Konstantinov SM, et al. J Cancer Res Clin Oncol. 2002, 128(5), 271-278. 4. Ackler S, et al. Br J Pharmacol. 2012. 5. Chow KU, et al. Biochem Pharmacol. 2003, 66(5), 711-724. 6. Minbo Zang, et al. Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice. J Biomed Res. 2017 0(0): 1-12. 7. Zhao X, Wang M Y, Jiang H, et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma[J]. Cell Reports. 2021, 34(11): 108870.